Heterocyclic Compounds

Matches 251 - 300 out of 36,785	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/026410A2	NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) INHIBITORS AND METHODS USING SAME The present disclosure relates to compounds which inhibit one or more members of the neurotrophic receptor tyrosine kinase (NTRK) family (i.e., NTRK1, NTRK2, and/or NTRK3), and pharmaceutical compositions thereof. In another aspect, the ...
WO/2024/017863A1	NOVEL PYRIMIDINYL AND TRIAZINYL SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula (I) wherein R4, R5, X1, X2, X3 and Y1 are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/017856A1	NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/020517A1	3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITR ILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...
WO/2024/020380A1	QUINAZOLINE COMPOUNDS AND METHODS OF USE Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...
WO/2024/017131A1	HETEROARYLOPIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF The present invention belongs to the field of medicine, and in particular relates to a heteroarylopiperidine derivative, and a pharmaceutical composition and the use thereof. The heteroarylopiperidine as represented by formula (I) provid...
WO/2024/018403A1	SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME The present disclosure includes substituted imidazoamide compounds of Formula (I), analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and...
WO/2024/017227A1	SUBSTITUTED FUSED RING CANNABINOID RECEPTOR COMPOUND AND USE THEREOF Provided is a cannabinoid receptor compound as represented by formula I. The compound has a good ability to bind to the human CB2 receptor, and exhibits good agonistic activity and high selectivity on the CB2 receptor. Consequently, said...
WO/2023/250157A9	INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
WO/2024/017144A1	SUBSTITUTED IMIDAZO [1, 2-A] PYRIDINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND PREVENTION OF FIBROSIS Provied are a class of substituted imidazo[1,2-a]pyridine compounds, pharmaceutical compositions containing the same, and use of the compounds in the treatment and prevention of fibrosis.
WO/2024/020419A1	AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE Substituted aza-quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspe...
WO/2024/020084A1	HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 Provided herein are compounds and compositions thereof for modulating IRAK4. In some embodiments, the compounds and compositions are provided for treatment of inflammatory or autoimmune diseases.
WO/2024/020068A1	BACTERIAL TOPOISOMERASE INHIBITORS Disclosed are bacterial topoisomerase inhibitors with antibacterial activity, including against fluoroquinolone-resistant Staphylococcus aureus, comprising structural domains: a) a left-hand side (LHS) usually comprising a fused bicyclic...
WO/2024/017855A1	NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, X and Y are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/020034A1	CBL-B INHIBITORS AND METHODS OF USE THEREOF Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula (II), and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment ...
WO/2024/017924A1	NLRP3 INHIBITORS The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4 and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/018915A1	COMPOUND, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE The purpose of the present invention is to provide a light-emitting element having excellent luminous efficiency and durability.　The present invention provides a compound which is represented by general formula (1). In general formula ...
WO/2024/017294A1	PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR Disclosed are a compound represented by formula I, a stereoisomer, deuterated product or pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, as well as a use thereof as a BRAF modulator in the prepa...
WO/2024/017201A1	CBL-B INHIBITORS AND METHODS OF USES THEREOF Provided for compounds and methods for modulating or inhibiting CBL-B.
WO/2024/017977A1	IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Compound are provided which can inhibit ERK5. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers.
WO/2024/017857A1	NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/012557A1	ANTI-APOPTOTIC BCL-2 FAMILY PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Provided herein are anti-apoptotic BCL-2 family protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or m...
WO/2024/015827A1	SOLID FORMS OF A TRIAZINE DERIVATIVE AS CBL-B MODULATOR The present disclosure provides, in part, provides crystalline forms of the compound of formula (I). Also provided are pharmaceutical compositions including a crystalline form of the compound of formula (I), as well as the crystalline fo...
WO/2024/012409A1	COMPOUNDS AS MYT1 INHIBITORS Disclosed in the present invention are compounds as MYT1 inhibitors. Particularly, the present invention relates to compounds represented by general formula (1) and a preparation method therefor, as well as the use of the compounds of ge...
WO/2024/012512A1	CARBAZOLE DERIVATIVE AND ORGANIC LIGHT-EMITTING ELEMENT HAVING SAME Provided are a carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I), and the carbazole derivative has a condensed carbazole structure. The compound can be applied to an org...
WO/2024/012449A1	COMPOUND CONTAINING TRIFLUOROMETHYL GROUP The present application provides a compound containing a trifluoromethyl group, and specifically relates to a compound as represented by formula I-0 or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmace...
WO/2024/012519A1	PAN-KRAS INHIBITOR Provided in the present invention are a fused ring aromatic compound having a broad-spectrum inhibition effect on KRAS mutation, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. As shown in formula ...
WO/2024/011294A1	ANTI-GIARDIAL COMPOUNDS The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...
WO/2024/012507A1	BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF Provided are a bicyclic compound represented by formula (I) or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, an atropisomer, a polymorph, a solvate, or an isotope labeled compound thereof. The compound re...
WO/2023/164234A9	COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing bloo...
WO/2024/012308A1	PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF A PRMT5 inhibitor, a preparation method therefor, and the pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical co...
WO/2024/012425A1	HETEROCYCLIC COMPOUND AS RIPK1 INHIBITOR The present invention relates to a compound, a pharmaceutical composition containing same, a preparation method therefor, and the use thereof as an RIPK1 inhibitor. The compound is a compound as represented by formula (I), or an optical ...
WO/2024/012469A1	CARBAZOLE DERIVATIVE AND USE THEREOF IN ORGANIC LIGHT-EMITTING ELEMENT The present invention relates to a carbazole derivative and use thereof in an organic light-emitting element. The carbazole derivative has a fused carbazole structure, a high triplet state energy level is achieved, and conjugation of a c...
WO/2024/012572A1	PHARMACEUTICAL COMPOSITION OF HETEROARYL DERIVATIVE AND MEDICAL USE THEREOF A pharmaceutical composition or a pharmaceutical preparation, the pharmaceutical composition or the pharmaceutical preparation comprising a therapeutically effective amount of an active ingredient M and a pharmaceutically acceptable exci...
WO/2024/015731A1	FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS Dislcosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or dis...
WO/2023/280638A9	VINYL THIANTHRENIUM COMPOUND, PROCESS FOR ITS PREPARATION AND ITS USE FOR TRANSFERRING A VINYL GROUP The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
WO/2024/012543A1	COMPOUND USED AS CDK4 INHIBITOR AND USE THEREOF Disclosed are a compound used as a cyclin-dependent kinase (CDK) 4 (CDK4) inhibitor and a use thereof. The specifically disclosed compound has a structure represented by formula I, wherein the definitions of groups and substituents are a...
WO/2024/015825A1	PROCESSES FOR PREPARING 5-BROMO-3,4-DIMETHYLPYRIDIN-2-AMINE AND 6-BROMO-7,8-DIMETHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE Disclosed are processes for preparing 5˗bromo˗3,4˗dimethylpyridin˗2˗amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine: (I), (VI).
WO/2024/015408A1	INDAZOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
WO/2024/014885A1	NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF The present invention provides a novel compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. With an excellent inhibitory activity against PIKfyve, the novel compound of the...
WO/2024/015861A1	METHODS OF PREPARATION OF HETEROCYCLIC COMPOUNDS Provided herein are methods of preparation of compound 101. Also provided are intermediate compounds useful in the preparation of compound 101, and methods of preparation of those intermediate compounds.
WO/2024/015637A1	GLUTATHIONE PEROXIDASE 4 (GPX4) INHIBITORS FOR THE TREATMENT OF CANCER The application relates to relates to glutathione peroxidase 4 (GPX4) inhibitors of the general Formulae I and II which induce ferroptosis in a cell and are useful for the treatment of cancer.
WO/2024/007985A1	PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF The present application provides a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same. The compound, the stereoisomer of the compoun...
WO/2024/008113A1	FORMAMIDE-SUBSTITUTED HETEROTRICYCLIC DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF The present invention relates to a formamide-substituted heterotricyclic derivative represented by formula (I), a method for preparing same, and use thereof. The present invention further relates to a pharmaceutical composition comprisin...
WO/2024/008185A1	PHARMACEUTICAL COMPOSITION CONTAINING SOS1 INHIBITOR Disclosed is a pharmaceutical composition containing an SOS1 inhibitor. The provided pharmaceutical composition containing an SOS1 inhibitor comprises an SOS1 inhibitor and an inhibitor A. The SOS1 inhibitor is a compound represented by ...
WO/2024/008179A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D.
WO/2024/010050A1	AMINE COMPOUND, AND ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC EQUIPMENT, AND ELECTRONIC ELEMENT CONTAINING SAME [Problem] The purpose of the present invention is to provide a compound that prevents internal elemental deterioration of an organic EL element, that, in order to significantly improve light-extraction efficiency, does not affect materia...
WO/2024/008121A1	DIFLUORO-SUBSTITUTED AZABICYCLO COMPOUNDS AND USES THEREOF Disclosed are a series of difluoro-substituted azabicyclo compounds and uses thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.
WO/2024/010782A1	PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...
WO/2024/008833A1	PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY A prodrug kit for multifactorial dynamic chemotherapy comprises N different small-molecule- drug-conjugates selected from the group comprising Si = Fci―Li―Cti with i = 1, 2, 3, …., 360 wherein 2 ≤ N ≤ 360, Fci is a moiety that ...

Matches 251 - 300 out of 36,785	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >